T1	PROC 234 265	evaluar la seguridad y eficacia
T2	PROC 49 110	estudio para evaluar la seguridad a largo plazo y la eficacia
T3	PROC 195 228	Estudio en fase II, multicéntrico
T4	CHEM 283 290	MT 1303
T5	DISO 308 349	esclerosis múltiple remitente recidivante
T6	CHEM 382 389	MT 1303
T7	DISO 417 436	Esclerosis múltiple
#1	AnnotatorNotes T7	C0026769; Multiple Sclerosis; Disease or Syndrome
T8	DISO 463 504	Esclerosis múltiple remitente recidivante
T9	PROC 566 577	tratamiento
#2	AnnotatorNotes T9	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T10	CHEM 604 611	MT 1303
T11	PROC 625 634	protocolo
#3	AnnotatorNotes T11	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T12	PROC 665 703	Suspensión permanente de la medicación
T13	CHEM 693 703	medicación
#4	AnnotatorNotes T13	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T14	PROC 748 759	tratamiento
#5	AnnotatorNotes T14	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T15	CHEM 778 785	MT 1303
T16	DISO 794 811	Diabetes mellitus
#6	AnnotatorNotes T16	C0011849; Diabetes Mellitus; Disease or Syndrome | C1802373; Diabetes mellitus (incl subtypes); Disease or Syndrome
T17	PROC 819 832	diagnosticada
#7	AnnotatorNotes T17	C0011900; Diagnosis; Diagnostic Procedure
T18	CHEM 852 859	MT 1303
T19	CHEM 114 121	MT-1303
#8	AnnotatorNotes T19	C4548795; MT-1303; Organic Chemical · Pharmacologic Substance
T20	DISO 506 510	EMRR
T21	CHEM 160 167	MT-1303
#9	AnnotatorNotes T21	C4548795; MT-1303; Organic Chemical · Pharmacologic Substance
T22	Date 13 17	2012
T23	Date 83 96	a largo plazo
T24	LIVB 125 132	sujetos
#10	AnnotatorNotes T24	C0681850; Study Subject; Group
T25	Date 266 279	a largo plazo
T26	LIVB 294 303	pacientes
#11	AnnotatorNotes T26	C0030705; Patients; Patient or Disabled Group
T27	Duration 581 591	24 semanas
T28	CONC 738 759	final del tratamiento
T29	PROC 728 734	visita
#12	AnnotatorNotes T29	C1512346; Patient Visit; Health Care Activity
A1	Status T9 History_of
A2	Status T10 History_of
A3	Status T14 History_of
A4	Status T15 History_of
A5	Status T6 History_of
#13	AnnotatorNotes T1	C0511730; Identify product efficacy and safety issues; Health Care Activity
#14	AnnotatorNotes T4	C4548795; MT-1303; Organic Chemical · Pharmacologic Substance
#15	AnnotatorNotes T15	C4548795; MT-1303; Organic Chemical · Pharmacologic Substance
#16	AnnotatorNotes T18	C4548795; MT-1303; Organic Chemical · Pharmacologic Substance
#17	AnnotatorNotes T10	C4548795; MT-1303; Organic Chemical · Pharmacologic Substance
#18	AnnotatorNotes T3	C0282460; Phase 2 Clinical Trials; Research Activity + C1096776; Multicenter Study; Research Activity
#19	AnnotatorNotes T5	C0751967; Multiple Sclerosis, Relapsing-Remitting; Disease or Syndrome
#20	AnnotatorNotes T8	C0751967; Multiple Sclerosis, Relapsing-Remitting; Disease or Syndrome
#21	AnnotatorNotes T20	C0751967; Multiple Sclerosis, Relapsing-Remitting; Disease or Syndrome
#22	AnnotatorNotes T6	C4548795; MT-1303; Organic Chemical · Pharmacologic Substance
#23	AnnotatorNotes T23	C0443252; Long-term; Temporal Concept
#24	AnnotatorNotes T25	C0443252; Long-term; Temporal Concept
R1	Overlap Arg1:T29 Arg2:T28	
R2	Overlap Arg1:T2 Arg2:T23	
R3	Experiences Arg1:T24 Arg2:T19	
R4	Experiences Arg1:T24 Arg2:T21	
T30	Observation 137 159	completaron el estudio
#25	AnnotatorNotes T30	C2732579; Completion of clinical trial; Finding
R6	Overlap Arg1:T1 Arg2:T25	
R7	Experiences Arg1:T26 Arg2:T4	
R8	Experiences Arg1:T26 Arg2:T5	
T31	Observation 360 381	completado el estudio
#26	AnnotatorNotes T31	C2732579; Completion of clinical trial; Finding
R10	Experiences Arg1:T26 Arg2:T6	
A6	Status T21 History_of
R11	Has_Duration_or_Interval Arg1:T9 Arg2:T27	
R12	Used_for Arg1:T10 Arg2:T9	
T32	Observation 538 577	Finalización del periodo de tratamiento
#27	AnnotatorNotes T32	C0580352; Treatment completed; Finding
R13	Used_for Arg1:T13 Arg2:T12	
R14	Before Arg1:T12 Arg2:T29	
R15	Used_for Arg1:T15 Arg2:T14	
R16	Used_for Arg1:T15 Arg2:T12	
A7	Status T13 History_of
T33	PROC 844 851	estudio
#28	AnnotatorNotes T33	C0008976; Clinical Trials; Research Activity
R17	Overlap Arg1:T16 Arg2:T33	
R18	Overlap Arg1:T17 Arg2:T33	
A8	Experiencer T24 Patient
A9	Experiencer T26 Patient
